Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer

The Oncologist
William B Ershler

Abstract

Optimal management for metastatic breast cancer frequently involves cytotoxic chemotherapy. Over the years, several complex multidrug regimens have been developed that were based upon a rationale of synergistic antitumor activity and nonoverlapping toxicities. However, recently the clinical value of these complex regimens has been called into question as several drugs used alone (monotherapy) or in sequence (serial single agent) have been shown to be both efficacious and better tolerated. Capecitabine (an orally administered fluoropyrimidine carbamate) is one such agent that has been proven to be effective when used alone for metastatic breast cancer, metastatic colorectal cancer, and adjuvant colon cancer. In this review, published (or reported in abstract form) data examining various aspects of clinical response and tolerability with single-agent capecitabine for (primarily) first- and second-line metastatic breast cancer are examined. For the most part, response rates are comparable with those of the more complex regimens. Dose reductions from the labeled dose of 1,250 mg/m(2) twice daily are relatively common. Toxicities (following dose reductions if needed) are generally manageable, even by more frail patients. Elderly pat...Continue Reading

References

Aug 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K A MargolinC Blevins
Feb 1, 1991·American Journal of Clinical Oncology·C L LoprinziC J Allegra
Jul 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S M SwainC J Allegra
Apr 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J H DoroshowE Newman
Jul 1, 1994·British Journal of Cancer·D A CameronR C Leonard
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G LiuE Warner
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M MiwaH Ishitsuka
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J L BlumT Griffin
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J F BishopR Canetta
Jan 1, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J SjöströmJ Bergh
Mar 20, 2002·Clinical Journal of Oncology Nursing·D Timmerman
Nov 28, 2002·The Oncologist·Joyce O'ShaughnessyMatti Aapro
Feb 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George W SledgeWilliam C Wood
Jul 26, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P ReichardtH J Lück
Aug 5, 2003·The Oncologist·Jeffrey S RossKenneth J Bloom
Feb 14, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P FumoleauM Namer
Oct 19, 2004·Seminars in Oncology·Robert LeonardChris Twelves
Nov 27, 2004·Breast Cancer Research and Treatment·J Y PiergaUNKNOWN Cooperative Group of the French capecitabine compassionate use program
Feb 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Emilio BajettaRoberto Buzzoni
Jul 2, 2005·Gynäkologisch-geburtshilfliche Rundschau·Laura Biganzoli, Matti Aapro

❮ Previous
Next ❯

Citations

Dec 23, 2008·Breast Cancer Research and Treatment·Joseph Gligorov, Jean-Pierre Lotz
Jul 18, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S BeslijaUNKNOWN Central European Cooperative Oncology Group (CECOG)
Nov 27, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E M CiruelosJ Baselga
Dec 22, 2009·American Journal of Clinical Oncology·Deborah L Toppmeyer, Susan Goodin
Feb 6, 2014·PloS One·Jing LuYu-Dong Cai
Apr 21, 2012·Pharmacogenomics·Anna González-Neira
Jan 11, 2013·Expert Opinion on Drug Metabolism & Toxicology·Gennaro DanieleAntonella De Luca
May 27, 2011·Seminars in Oncology·Monica N Fornier
Aug 28, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M KaufmannUNKNOWN GBG-39 Trialists
May 22, 2007·Hematology/oncology Clinics of North America·Erica L Mayer, Harold J Burstein
Jul 30, 2009·Pharmacotherapy·Serena T Wong, Susan Goodin
Nov 29, 2015·Clinics in Geriatric Medicine·Meghan KaruturiHyman Muss
May 16, 2015·Breast Cancer Research and Treatment·Yong WuJaydutt V Vadgama
Mar 14, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·José BaselgaFrederico Costa
Oct 7, 2006·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Sarah M GressettFred Hardwicke
Feb 3, 2012·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Debi BhattacharyaSteven Watson
Jan 19, 2019·Pharmaceutical Patent Analyst·Marcella Bassetto, Magdalena Slusarczyk
Sep 21, 2017·Future Medicinal Chemistry·Alessandra CavaliereMagdalena Slusarczyk
Mar 23, 2017·Future Oncology·Vito LorussoSandro Barni
Jul 1, 2010·Oncology Letters·Takehiro NoharaNobuhiko Tanigawa

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
E BajettaR Buzzoni
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
P FumoleauM Namer
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
M KaufmannGBG-39 Trialists
© 2022 Meta ULC. All rights reserved